ResMed Inc. (ASX:RMD) Reports Q1 2025 Financial Results
Financial Performance
ResMed Inc. reported Q1 2025 net revenue of $1.29 billion, representing an 8% increase year-over-year. Gross margin improved to 59.3% from 57.9% in the previous year. Diluted earnings per share rose to $2.48 from $2.04. For the nine months ended March 31, 2025, net revenue reached $3.80 billion, a 10% increase compared to the same period in 2024, with diluted EPS increasing to $6.93 from $4.94.
Dividend Declaration
The company declared a cash dividend of $0.53 per common share, to be paid on June 12, 2025, to shareholders of record as of May 8, 2025.
Motley Fool contributor Matt Burgess has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
